AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute MI

RecruitingNAAges 19 Years - anyAllSamsung Medical Center
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The aim of the study is to compare clinical outcomes between intravascular ultrasound (IVUS)-guided treatment decision versus fractional flow reserve (FFR)-guided treatment decision for non-infarct related artery stenosis in patients with acute myocardial infarction (AMI) and multivessel disease.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Subject must be at least 19 years of age * Acute ST-segment elevation myocardial infarction (STEMI) \*STEMI: ST-segment elevation โ‰ฅ0.1 mV in โ‰ฅ2 contiguous leads or documented newly developed left bundle-branch block * Acute non-ST-segment elevation myocardial infarction (NSTEMI) \*NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following: 1. Symptoms of ischemia. 2. New or presumed new significant ST-T wave changes 3. Development of pathological Q waves on electrocardiography. 4. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality. 5. Intracoronary thrombus detected on angiography. * Successful primary percutaneous coronary intervention (PCI) in \< 12 h after the onset of symptoms for STEMI patients (In case of NSTEMI, PCI should be performed within 72 hours of symptom onset) * Multivessel disease (at least one stenosis of \>50% in a non-IRA โ‰ฅ2.25 mm by visual estimation) * Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure. Exclusion Criteria: * Non-IRA stenosis not amenable for PCI treatment by operators' decision * Cardiogenic shock (Killip class IV) already at presentation or the completion of IRA PCI * Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus * Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock) * Pregnancy or breast feeding * Non-cardiac co-morbid conditions are present with life expectancy \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment) * Other primary valvular disease with severe degree: severe mitral regurgitation, mitral stenosis, severe aortic regurgitation, or aortic stenosis * Unwillingness or inability to comply with the procedures described in this protocol.
๐Ÿ’Š

What it tests

  • IVUS-guided PCI group
  • FFR-guided PCI group
๐Ÿ“

Where

2 sites
Chonnam National University
Gwangju, South Korea
Samsung Medical Center
Seoul, South Korea
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy